Abstract
We have examined the cellular processes underlying the desensitization of the 5-hydroxytryptamine (5-HT)2A receptor induced by agonist or antagonist exposure. Treatment of C6 glioma cells with either 5-HT or the 5-HT2A receptor antagonist ketanserin resulted in an attenuation in 5-HT2A receptor function, specifically the accumulation of inositol phosphates stimulated by the partial agonist quipazine. 5-HT-induced desensitization of the 5-HT2A receptor involved receptor internalization through a clathrin- and dynamin-dependent process because it was prevented by concanavalin A, monodansylcadaverine, and by expression of the dominant negative mutants β-arrestin (319–418) and dynamin K44A. Although short-term (i.e., 10 min) 5-HT and ketanserin exposure resulted in the same degree of desensitization, ketanserin-induced desensitization was not prevented by these agents and did not involve receptor internalization. In contrast, prolonged ketanserin exposure (i.e., 2 h) resulted in 5-HT2A receptor internalization through a clathrin- and dynamin-dependent process, as was observed after agonist treatment. Inhibitors of protein kinase C or calcium-calmodulin kinase II did not attenuate or prevent 5-HT-induced desensitization of the receptor. 5-HT2A receptor desensitization induced by 5-HT and prolonged ketanserin treatment, but not by short-term ketanserin treatment, was prevented by the expression of the dominant negative mutant of G protein-coupled receptor kinase (GRK)2, GRK2-K220R, and by an anti-GRK2/3 antibody. Our data indicate a dual mechanism of early and late desensitization by the antagonist ketanserin. Short-term ketanserin treatment reduced the specific binding of the agonist radioligand [125I](±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ([125I]DOI) and the ability of 5′-guanylylimidodiphosphate to attenuate this binding, suggesting that at the early stage of antagonist-induced desensitization the capacity of the 5-HT2A receptor to couple to G protein is impaired.
Footnotes
-
This research was supported by U.S. Public Health Service Grant MH 52369 and funds from the South Texas Health Research Center (to J.G.H.). N.R.S.H. is the recipient of a Fellowship for Advanced Predoctoral Training in Pharmacology and Toxicology from the Pharmaceutical Research and Manufacturers of America Foundation.
- Abbreviations:
- GRK
- G protein-coupled receptor kinase
- 5-HT
- 5-hydroxytryptamine (serotonin)
- IP
- inositol phosphates
- PI
- phosphoinositol
- PBS
- phosphate-buffered saline
- DOI
- (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
- ELISA
- enzyme-linked immunosorbent assay
- TBS
- Tris-buffered saline
- con A
- concanavalin A
- MDC
- monodansylcadaverine
- PKC
- protein kinase C
- GppNHp
- 5′-guanylylimidodiphosphate
- Received July 9, 2001.
- Accepted October 31, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|